Purpose The purpose of this study was to compare the effects of ormeloxifene with medroxyprogesterone acetate in patients with abnormal uterine bleeding. Material and Method 440 Patients were divided into two groups. In group A, ormeloxifene was given at the dosage of 60 mg twice a week for 3 months followed by 60 mg once a week for 1 month. In group B, medroxyprogesterone acetate was given at the dosage of 10 mg twice a day from day 5 to day 25 of the menstrual cycle. At followups, patients were assessed for PBAC score, endometrial thickness by USG, hemoglobin level, and the side effects of drug therapy. Results There were 240 patients in group A and 200 in group B. Reduction in median PBAC score was 79.4 % in group A and 75 % in group B after 4 months of treatment. The mean duration of bleeding reduced to 4.8 from 9 in group A and 5 from 8.7 in group B. Mean hemoglobin was increased from 8.6 to 9.8 g % in group A and from 8.7 to 9.9 g % in group B; endometrial thickness was reduced 123 from 7.7 mm to 6.8 mm in group A and from 7.4 mm to 6.9 mm in group B.
Introduction
Abnormal uterine bleeding (AUB) is defined as bleeding from uterine corpus which is abnormal in regularity, volume, frequency, and duration of bleeding, and it occurs in the absence of pregnancy [1] . It can be acute and chronic. It is one of the major gynecological problems affecting women's wellbeing for which women seek health personnel. In a national study of the United States, the authors found that menstrual disorders were the reason for 19.1 percent of 20.1 million visits to doctors' clinics for gynecological conditions over a two-year period [2] . Any patient with AUB should be evaluated regarding her clinical status and severity, etiology, and the most appropriate treatment. The new classification (Table 1) system of etiology of AUB has been proposed by the Menstrual Disorders Working Group of the International Federation of Gynecology and Obstetrics [1] .
Surgical treatment is often needed for all structural causes, while for the nonstructural causes, medical treatment should be the first choice. The choice of treatment depends on the cause, age, severity of bleeding, fertility status, need for contraception, and the treatment available at the center. Among the medical category, there are various options as combined oral contraceptives, progestins (oral or intramuscular), levonorgestrel intrauterine device, antifibrinolytics such as tranexemic acid and danazol, gonadotropins releasing hormone, etc., but every treatment option has its own benefits and risks, and in some cases cost is also an issue. In the literature, still there is no gold standard treatment for AUB. Ormeloxifene is a newer non-steroidal alternative for the treatment of AUB. However, there are limited number of studies available on its efficacy and safety. It is also known as centchroman, a nonsteroidal, selective estrogen receptor modulator (SERM), with potent estrogen antagonistic action on uterus as well as breast tissue and mild agonistic action on bone mineral density [3, 4] . It is very effective, reducing up to 70 % blood loss with minimal side effects, has an easy dosing schedule, and cost efficient [5] .
Materials and Methods
A total of 440 patients with AUB were included in this study, aged between 20 and 50 years. Patients with leiomyoma, adenomyosis, polyp, adnexal mass, systemic disorder, coagulopathy, breast malignancy, or endometrial hyperplasia with atypia were excluded. Patients were divided into two groups. In group A, ormeloxifene was given at the dosage of 60 mg twice a week for 3 months followed by 60 mg once a week for 1 month. In group B, medroxyprogesterone acetate (MPA) was given at the dosage of 10 mg twice a day from day 5 to day 25 of the menstrual cycle. After detailed history and clinical examination, every patient was subjected to the assessment of Pictorial blood loss assessment chart (PBAC) scoring, hemoglobin level, endometrial thickness on ultrasonography, and endometrial biopsy and Pap smear. Follow-up was done at 2nd and 4th month, and again at each follow-up their clinical characteristics of bleeding, PBAC score, hemoglobin level, and endometrial thickness were assessed and the side effects of therapy, if any, were also noted.
Pictorial blood loss assessment chart (PBAC) is used to measure the amount of menstrual blood loss [6] . In this method, women are asked to use certain sanitary napkins which have similar absorbent capacities. They record the number of napkins used in a cycle. Number and size of clots passed are also noted. Scores are assigned to different degrees of soiling of sanitary napkins and number and size of clots passed. Scores of 1, 5, 20 are given to slightly soiled, moderately soiled, and saturated pad, respectively. Score 1 is given to the small clot and 5 to the large clot. PBAC score up to 10 is considered as scanty flow, 10-100 as moderate flow, 100-300 as heavy flow, and more than 300 as very heavy flow. PBAC score more than 100 is considered as blood loss more than 80 ml diagnostic of menorrhagia [6] . Degree of anemia was also noted. Hemoglobin level of 7-9 g % was considered as moderate anemia, 9-11 g % as mild anemia, and hemoglobin [11 g % as no anemia. P values, t score of both groups, and t score of group A versus group B were calculated.
Results
There were a total of 440 patients in our study. 240 patients were in group A and 200 patients were in group B. Mean age in group A was 38.16 ± 6.8 years, while in group B, it was 35.5 ± 6.9 years. Mean parity of group A was 3.9 ± 0.95, while that of group B was 3.4 ± 1.2. No statistical difference was found between age and parity distribution in both the groups. The effects of each drug on amount of blood loss (PBAC score) during menstruation were noted at each follow-up, as shown in Table 2 . Incidence of amenorrhea was more in group A than that in group B after treatment. The effect of the drug on group B developed gradually (less efficient): at first follow-up only 80 (41.6 %) patients had blood loss, \80 ml, but at the second follow-up 144 (83.3 %) had blood loss \80 ml (similar efficacious to ormeloxifene). In group A, at first follow-up, 184 (82.1 %, more efficient than MPA) patients were relieved of menorrhagia, and at the second follow-up 192 (86.6 %, similar efficacious to MPA) patients had blood loss \80 ml. Comparisons of clinical characteristics of pre-and post-treatment between both the groups are shown in Table 3 . The mean duration of bleeding was 9 and 8.7 days before treatment which was reduced to 4.8 and 5 days after 4 months of treatment in group A and group B, respectively. The reduction in median PBAC score was 79.4 % in group A and 75 % in group B after 4 months of treatment. The reduction was statistically significant in both the groups. The increment in mean hemoglobin was 1.4 g % in group A and 1.2 g % in group B after treatment, which was also statistically significant in both the groups. After treatment, a statistically significant reduction in mean endometrial thickness was seen in both the groups (0.91 mm in group A and 0.5 mm in group B). No major side effects were seen in our study in both the groups. In group A, 32 (13.3 %) patients developed cervical discharge, and 16 (6.7 %) patients developed vague abdominal pain. In group B, 32 (16 %) patients complained of weight gain, 40 (20 %) patients complained of intermenstrual spotting, and 16 (8 %) patients developed dyspepsia.
In our study, 24 patients showed a lack of response after 4 months of treatment with ormeloxifene. The mean PBAC score of these patients was 446 before treatment which reduced to 310 (30.4 % reduction) and 460 (3.1 % increment) after 2 and 4 months of treatment, respectively. Initially, they showed good response at 2 months of treatment but they again developed increased blood loss after 4 months. Out of 24, 7 had simple endometrial hyperplasia initially and on repeat biopsy they showed complex hyperplasia without atypia. Seven patients underwent hysterectomy by their choice and 10 patients were lost to follow up.
After treatment with medroxyprogesterone, 56 (28 %) and 24 (12 %) patients showed a lack of response after 2 and 4 months of treatment. The mean PBAC score of these patients was 422 before treatment which increased to 424 (0.47 % increment) and 433.3 (2.7 % increment) after 2 and 4 months of treatment, respectively. All of them showed no response throughout the treatment period. Ten patients underwent hysterectomy during treatment period in this group. Fourteen patients were lost to follow up.
As shown in Table 4 , the differences in pre-treatment and post-treatment values are statistically significant in each group, but no statistical significant difference was found between the effects of both the drugs. Effect of ormeloxifene in AUB was comparable to medroxyprogesterone in terms of reduction in passage of clots, reduction in PBAC score, improvement in hemoglobin concentration, and reduction in endometrial thickness.
Discussion
AUB is a major and one of the most distressing gynecological problems for both patient and clinician. In a study by Deeksha Pandey, AUB was the third most common indication of hysterectomy after fibroid and prolapse [7] . Hysterectomy has its own known complications as any other major surgery. In low resource settings where women are underprivileged, anemic, having lesser access to good treatment, due to poverty, ignorance, and illiteracy, they usually undergo surgery for their problem in small hospitals with less trained staff, exposing themselves at risk of higher morbidity and mortality. There should be an effective conservative treatment for AUB and menorrhagia and surgery to be resorted in absolutely necessary cases. Ormeloxifene is one of the effective and safe choices for abnormal uterine bleeding. Oral contraceptive pills are associated with daily dosing, nausea, breast tenderness, and weight gain, so the patient compliance is poor. Levonorgestrel intrauterine devices are very effective in treating menorrhagia, but its cost is too high for their routine use. Ormeloxifene is a good alternative to save the patient from hysterectomy. Twice weekly schedule, low cost, minimal side effects, and reducing up to 70 % blood loss with faster response all these facts make ormeloxifene a good option in medical management of AUB [5] . The results of this study are comparable to other studies also. Incidence of amenorrhea was reported to be 9.5 % in a study by Sharvage et al. [8] , while Komaram et al. [9] found it to be 10 %. We found incidence of amenorrhea to be 14.1 % in our study.
In a double-blind randomized controlled trial of ormeloxifene versus MPA in dysfunctional uterine bleeding (DUB), Shravage et al. found that the reduction in the mean PBAC score was 85.71 % with ormeloxifene and 54.76 % with MPA after 4 months of treatment [8] . The result with ormeloxifene is nearly similar to our study (79.4 %), but the result with MPA in their study was less efficacious than ormeloxifene. The reason may be the insufficient dose of MPA. They administered only 10 mg of MPA daily, while we gave 20 mg daily for 21 days.
Komaram et al. [8] found that the mean endometrial thickness was reduced from 11.67 mm to 9.3 mm (20.3 % reduction) after 4 months of treatment, which is more than our study (11.6 % reduction). The reason might be that their pre-treatment endometrial thickness was also higher than our study. In a study by Kriplani et al. [5] , the mean hemoglobin was increased to 11.2 g % from 10.6 g %, while Komaram et al. [9] found an increment in hemoglobin from 9.2 to 10.5 g %. These results are similar to that of our study. We concluded from this study that ormeloxifene being a non-steroidal drug should be considered the first choice in the management of AUB, especially in the perimenopausal age group where amenorrhea is acceptable. Weaknesses of this study are relatively small duration of follow-up and non-randomization, but still our results are reliable because of sufficient sample size, excellent patient registry, and strict adherence to assessment method. A large randomized controlled trial is needed to further validate the results by comparing its efficacy and efficiency with other hormonal preparation.
Compliance with Ethical Standards
Conflict of interest The authors declare that they have no conflict of interest regarding this study and its publication. Informed consent Informed consent was obtained from all patients and hospital ethical board for study and publication.
